SLN 8-K: SEC filing

Silence Therapeutics plc

Filed with the SEC on · accession 0001193125-26-457060

SLN filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Silence Therapeutics plc announced its financial and business results for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.

Key details

RegistrantSilence Therapeutics plc
Interim principal executive officer and chairman of the board of directorsIain Ross

✦ Ask GOAX AI about this filing — what it means for SLN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for SLN?

Click here

Frequently asked questions

What did SLN file with the SEC on Nov 12, 2026?

SLN filed a 8-K (SEC filing). Silence Therapeutics plc announced its financial and business results for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other SLN SEC filings

Get alerts when SLN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days